Onconetix (ONCO) to Post Earnings on Monday

Onconetix (NASDAQ:ONCO) will likely be posting its Q2 2026 resultson Monday, August 17th. Analysts expect Onconetix to announce earnings of ($4,505.00) per share and revenue of $0.0220 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, August 19, 2026 at 9:30 AM ET.

Onconetix Price Performance

NASDAQ:ONCO opened at $0.89 on Monday. The stock’s fifty day moving average is $0.95 and its two-hundred day moving average is $19.02. Onconetix has a 52 week low of $0.67 and a 52 week high of $209.50. The stock has a market capitalization of $1.02 million, a price-to-earnings ratio of 0.08 and a beta of 2.69.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Onconetix stock. Citadel Advisors LLC purchased a new stake in Onconetix, Inc. (NASDAQ:ONCO) during the third quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 15,633 shares of the company’s stock, valued at approximately $49,000. Citadel Advisors LLC owned approximately 1.00% of Onconetix at the end of the most recent reporting period. Institutional investors own 23.89% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on ONCO. Wall Street Zen downgraded Onconetix from a “hold” rating to a “sell” rating in a report on Saturday, May 23rd. Weiss Ratings raised shares of Onconetix from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, July 15th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company has an average rating of “Sell”.

About Onconetix

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.